EA200601016A1 - Применение дезоксипеганина для лечения шизофренических психозов - Google Patents

Применение дезоксипеганина для лечения шизофренических психозов

Info

Publication number
EA200601016A1
EA200601016A1 EA200601016A EA200601016A EA200601016A1 EA 200601016 A1 EA200601016 A1 EA 200601016A1 EA 200601016 A EA200601016 A EA 200601016A EA 200601016 A EA200601016 A EA 200601016A EA 200601016 A1 EA200601016 A1 EA 200601016A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
deoxypheanine
application
schizophrenic psychoses
schizophrenic
Prior art date
Application number
EA200601016A
Other languages
English (en)
Other versions
EA012033B1 (ru
Inventor
Йохим Моорманн
Клаус Опиц
Original Assignee
Хф Арцнаймиттельфоршунг Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34625212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хф Арцнаймиттельфоршунг Гмбх filed Critical Хф Арцнаймиттельфоршунг Гмбх
Publication of EA200601016A1 publication Critical patent/EA200601016A1/ru
Publication of EA012033B1 publication Critical patent/EA012033B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Применение дезоксипеганина в виде свободного основания или в виде кислой соли присоединения или производного дезоксипеганина, если названное производное одновременно является ингибитором ацетилхолинэстеразы и моноаминоксидазы, для изготовления лекарственного препарата для лечения шизофренического психоза.
EA200601016A 2003-11-24 2004-11-08 Применение дезоксипеганина для лечения шизофренических психозов EA012033B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10354893A DE10354893B4 (de) 2003-11-24 2003-11-24 Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
PCT/EP2004/012605 WO2005053673A1 (de) 2003-11-24 2004-11-08 Verwendung von desoxypeganin zur behandlung schizophrener psychosen

Publications (2)

Publication Number Publication Date
EA200601016A1 true EA200601016A1 (ru) 2006-10-27
EA012033B1 EA012033B1 (ru) 2009-06-30

Family

ID=34625212

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601016A EA012033B1 (ru) 2003-11-24 2004-11-08 Применение дезоксипеганина для лечения шизофренических психозов

Country Status (24)

Country Link
US (1) US20070072947A1 (ru)
EP (1) EP1725229B1 (ru)
JP (1) JP2007512269A (ru)
KR (1) KR20070085036A (ru)
CN (1) CN1886127A (ru)
AR (1) AR046664A1 (ru)
AT (1) ATE424197T1 (ru)
AU (1) AU2004294689B2 (ru)
BR (1) BRPI0416411A (ru)
CA (1) CA2547171A1 (ru)
DE (2) DE10354893B4 (ru)
DK (1) DK1725229T3 (ru)
EA (1) EA012033B1 (ru)
ES (1) ES2323645T3 (ru)
HK (1) HK1093696A1 (ru)
IL (1) IL175772A0 (ru)
MY (1) MY141730A (ru)
NO (1) NO20062666L (ru)
NZ (1) NZ547103A (ru)
SI (1) SI1725229T1 (ru)
TW (1) TW200607507A (ru)
UA (1) UA86951C2 (ru)
WO (1) WO2005053673A1 (ru)
ZA (1) ZA200603543B (ru)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression

Also Published As

Publication number Publication date
CN1886127A (zh) 2006-12-27
UA86951C2 (ru) 2009-06-10
HK1093696A1 (en) 2007-03-09
DE10354893A1 (de) 2005-06-30
NZ547103A (en) 2009-07-31
JP2007512269A (ja) 2007-05-17
AR046664A1 (es) 2005-12-14
ATE424197T1 (de) 2009-03-15
ES2323645T3 (es) 2009-07-22
EP1725229A1 (de) 2006-11-29
AU2004294689A1 (en) 2005-06-16
US20070072947A1 (en) 2007-03-29
ZA200603543B (en) 2007-03-28
IL175772A0 (en) 2008-04-13
KR20070085036A (ko) 2007-08-27
EP1725229B1 (de) 2009-03-04
TW200607507A (en) 2006-03-01
CA2547171A1 (en) 2005-06-16
WO2005053673A1 (de) 2005-06-16
EA012033B1 (ru) 2009-06-30
MY141730A (en) 2010-06-15
DE502004009105D1 (de) 2009-04-16
NO20062666L (no) 2006-06-09
DE10354893B4 (de) 2011-03-10
AU2004294689B2 (en) 2010-01-07
BRPI0416411A (pt) 2007-01-09
DK1725229T3 (da) 2009-06-22
SI1725229T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
EA200801341A1 (ru) КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
DE50310516D1 (de) Fredericamycin-derivate
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
NO20044995L (no) Heterosykliske forbindelser
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
DE60334536D1 (de) Furylverbindungen
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ECSP055844A (es) Nuevos compuestos triciclicos
NO20055741L (no) Nye kjemiske forbindelser
DE602005011113D1 (de) Morphinanderivate als mittel gegen juckreiz
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
DE602005010607D1 (de) Zyklosporinanalog
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
CY1109762T1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
SE0402284D0 (sv) New heterocyclic amides
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU